Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02944565 · OUTCOME

Total Daratumumab Infusion Time

Daratumumab in Treating Patients With Multiple Myeloma · Source last updated 2019-09-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
hours
Interval / dispersion
Full Range
Time frame
Up to 6 months

What was measured

The start and stop times of daratumumab infusion will be tracked during infusion acceleration.

Groups in this outcome

Treatment (Daratumumab)

Patients received daratumumab 16 mg/kg IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment (Daratumumab)28

Reported measurements

Source class 1
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Treatment (Daratumumab)1.5Not reported1.52.4Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        1.5
        upper Limit
        2.4
        value
        1.5
denoms
  1. counts
    1. group Id
      OG000
      value
      28
    units
    Participants
description
The start and stop times of daratumumab infusion will be tracked during infusion acceleration.
dispersion Type
Full Range
groups
  1. description
    Patients received daratumumab 16 mg/kg IV over 1.5 hours. Treatment continues in the absence of disease progression or unacceptable toxicity.
    id
    OG000
    title
    Treatment (Daratumumab)
param Type
MEDIAN
reporting Status
POSTED
time Frame
Up to 6 months
title
Total Daratumumab Infusion Time
type
PRIMARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice